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Abstract
Background: Interstitial fibrosis plays an important role in progressive renal dysfunction in autosomal dominant polycystic
kidney disease (ADPKD). In our previous studies, we confirmed that PPAR-c agonist, rosiglitazone could protect renal
function and prolong the survival of a slowly progressive ADPKD animal model by reducing renal fibrosis. However, the
mechanism remains unknown.
Methods: Primary culture epithelial cells pretreated with TGF-b1 were incubated with rosiglitazone. Extracellular matrix
proteins were detected using real-time PCR and Western blotting. MAPK and Smad2 phosphorylation were measured with
western blot. ERK1/2 pathway and P38 pathway were inhibited with the specific inhibitors PD98059 and SB203580. The
Smad2 pathway was blocked with the siRNA. To address whether PPAR-c agonist-mediated inhibition of TGF-b1–induced
collagen type I expression was mediated through a PPAR-c dependent mechanism, genetic and pharmaceutical approaches
were used to block the activity of endogenous PPARc.
Results: TGF-b1-stimulated collagen type I and fibronectin expression of ADPKD cyst-lining epithelia were inhibited by
rosiglitazone in a dosage-dependent manner. Smad2, ERK1/2 and P38 pathways were activated in response to TGF-b1;
however, TGF-b1 had little effect on JNK pathway. Rosiglitazone suppressed TGF-b1 induced Smad2 activation, while ERK1/2
and P38MAPK signals remained unaffected. Rosiglitazone could also attenuate TGF-b1-stimulated collagen type I and
fibronectin expression in primary renal tubular epithelial cells, but had no effect on TGF-b1–induced activation of Smad2,
ERK1/2 and P38 pathways. There was no crosstalk between the Smad2 and MAPK pathways in ADPKD cyst-lining epithelial
cells. These inhibitory effects of rosiglitazone were reversed by the PPARc specific antagonist GW9662 and PPARc siRNA.
Conclusion: ADPKD cyst-lining epithelial cells participate in TGF-b1 mediated fibrogenesis. Rosiglitazone could suppress
TGF-b1–induced collagen type I and fibronectin expression in ADPKD cyst-lining epithelia through modulation of the
Smad2 pathway. Our study may provide therapeutic basis for clinical applications of rosiglitazone in retarding the
progression of ADPKD.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the
most common life-threaten hereditary disease, caused by muta-
tions of either PKD1 or PKD2 which respectively encode
polycystin-1 (PC1) and polycystin-2 (PC2) [1].It affects 1 : 400 to
1 : 1000 live births and accounts for up to 10% of all patients on
renal replacement therapy[2,3]. There are two important stages in
the pathogenesis of ADPKD [4]. In the initial stage, numerous
fluid-filled epithelial cysts arise from different nephron segments as
spherical dilatations or small out-pouchings. In the progressive
stage, the cysts gradually increase in number and size over time
which is accompanied by interstitial fibrosis and decline of renal
function[2,3] While the cystogenesis itself is thought to be a
primary driver of organ injury, several studies have pointed out the
correlation between the interstitial fibrosis and the progression of
ADPKD [5,6,7]. Progression to end-stage cystic disease is
associated with the accumulation of extracellular matrix (ECM)
proteins such as collagen type I and fibronectin in the renal
interstitium.
Transforming growth factor-b1 (TGF-b1) is one of the most
important cytokines that participate in tubulointerstitial inflam-
mation and fibrosis [8,9]. It exerts its multiple biologic actions by
activating several intracellular signal transduction systems includ-
ing Smad-dependent [10] and Smad-independent pathways such
as the mitogen-activated protein kinase (MAPK) pathways,
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28915including extracellular signal–regulated kinase (ERK) [11,12,13],
Jun N-terminal kinase (JNK) [14], and p38 mitogen–activated
protein kinase (p38 MAPK) [15]. The expression of TGF-b1 and
TGF-b1-regulated genes were increased at more advanced stages
of polycystic kidney disease but was nearly unaltered at the early
stage of the disease in four PKD animal models, suggesting that
the TGF-b1 signalling pathway was probably not implicated in
initial steps of cyst formation but contributed to progression of
polycystic kidney disease [5]. In addition, several studies
performed on end-stage ADPKD kidneys suggested the involve-
ment of TGF-b1 signalling in polycystic kidney disease [16,17,18].
Peroxisome proliferator-activated receptor c (PPARc) belongs
to the superfamily of nuclear hormone receptor transcription
factors, which forms a heterodimer with another nuclear receptor,
retinoid X receptor (RXRa) [19]. PPARc was initially noted to be
highly expressed in adipose tissue and was found to have a
regulatory function in adipocyte differentiation, insulin sensitiza-
tion and lipid metabolism[20,21]. Recently, increasing evidence
indicates that PPARc has a close relation to the kidney diseases.
PPARc agonists possess antifibrotic potential that results in
attenuation of renal fibrosis after chronic injury. Of particular
interest, studies show that PPARc agonists not only are able to
ameliorate glomerulosclerosis and kidney dysfunctions in diabetic
nephropathy [22] but also exert beneficial actions in nondiabetic
chronic kidney disease [23,24]. For example, PPARc agonist
attenuates renal interstitial fibrosis and inflammation in the mouse
model of unilateral ureteral obstruction (UUO) [25]. We [26] and
another group [27] have previously demonstrated that PPAR-c
agonist could inhibit the progression of polycystic kidney disease in
PKD animal models by inhibiting cell proliferation and fibrosis.
Fibroblasts have been identified as the principal fibrogenic
precursor cell type in tubulointerstitial fibrosis. However, recent
studies have indicated that cyst-lining epithelial cells also play an
important role in the fibrogenic process in polycystic kidney
disease [5]. It has been well established that PPARc activation
exerts anti-fibrosis and anti-inflammation effects on mesangial
cells, fibroblast cells and tubular epithelial cells via the modulation
of TGF-b1-mediated pathways in vitro [28,29]. But whether
PPARc agonists can block TGF-b1 pathway in ADPKD cyst-
lining epithelia have not been studied until now. In the present
study, we examined the possible role of TGF-b1 in regulating
ECM production in primary culture human ADPKD cyst-lining
epithelia. In addition, we examined the role of rosiglitazone in
TGF-b1-induced ECM expression in human ADPKD cyst-lining
epithelia and investigated the underlying molecular mechanisms.
Materials and Methods
Ethics Statement
The biological study was approved by the Ethical Committee of
Second Military Medical University, Shanghai, China. Human
cystic kidney tissues were obtained after signed informed consent
from ADPKD patients who underwent nephrectomies because of
pre-transplantion or complications such as bleeding or pain.
Normal renal cortical tissues were obtained from kidneys that were
removed for circumscribed tumors. Histologic examination of
these kidney samples revealed no renal pathology.
Materials
Rosiglitazone, a known PPARc agonist, and irreversible PPARc
antagonist GW9662 were purchased from Cayman Chemical
Company (Ann Arbor, MI). TGF-b1 was obtained from R&D
(Minneapolis, MN). The ERK1/2 inhibitor PD98059, P38
inhibitor SB203580 and Dimethylsufoxide (DMSO) were pur-
chasedfrom Sigma(St.Louis, MO).A stock solutionofrosiglitazone
for cellular assays was prepared in DMSO and then diluted in the
optimal medium. Tissue culture media and FBS were purchased
from Gibco (Grand Island, NY). BCA reagents were from Pierce
(Rockford, IL). Antibody against pan-cytokeratin, a-smooth muscle
actin (a-SMA), fibronectin and GAPDH were purchased from
Sigma (St. Louis, MO). Antibody against vimentin was purchased
from Roche (Indianapolis, IN). Phosphorylated and non-phosphor-
ylated antibodies to Smad2, ERK1/2, JNK, p38MAPK antibody
were all purchased from Cell Signaling (New England, MA). Anti-
collagen I antibody was purchased from Abcam (Cambridge, MA).
Anti-TGF-b1 antibody and anti- E-cadherin antibody were
purchased from Santa Cruz (CA, USA).
Isolation and primary culture of human renal tubular
epithelial cells and ADPKD cyst-lining epithelial cells
Primary culture of human renal tubular epithelial cells (RTC)
were carried out according to a previously described method [30].
Briefly, renal cortical tissue was obtained from kidneys that were
removed for circumscribed tumors (three patients, 2 males, 1
female, aged 5868 years). Cortical specimens were cut into small
cubes and passed through a series of mesh sieves of diminishing
pore size. RTC were collected on the 53-mm sieve and digested
with collagenase (750 U/ml) at 37uC for 15 min. Tubular cells
were isolated by centrifugation and then plated in growth medium.
Cyst-lining epithelial cells (CEC)culture was carried out as Zhou
et al previously reported [31]. Briefly, cystic kidney tissues were
obtained from ADPKD patients (2 males, 1 female, aged 5266
years, CKD 5 stages). Genetic analysis was performed by PCR-
SSCP in our lab. All the ADPKD patients were diagnosed with
PKD1 mutation. Cyst tops were excised, washed extensively in
PBS, and incubated with 16trypsin-EDTA at 37uC for 15–
20 min. The tubes containing the cyst fragments were vortexed
vigorously every 5 min. Thereafter, ice-cold HBSS containing
10% FBS was added to inactivate trypsin. The cells were further
released from the fibrous cyst wall by trituration, washed twice
with HBSS, then centrifuged and resuspended in fresh culture
medium, and seeded on Pimaria culture plates.
CEC and RTC were grown in a 1:1 mixture of DMEM and
Ham’s F12 medium supplemented with 10% FBS, 5 mg/ml insulin,
5 mg/ml transferrin, 5 ng/ml selenium, 36 ng/ml hydrocortisone,
10
28 M triiodothyronine, 10 ng/ml EGF, and 50 ng/ml PGE1,a s
well as 100 U/ml penicillin, and 100 mg/ml streptomycin. After 2–
4 days, the cells became confluent and were subcultured with
medium containing 10% FBS. The in vitro experiments described
in this report were performed in passages 1–3 cells.
Immunocytochemistry
The primary culture cells were grown at 37uC for 4–5 days
before study. The cells were washed three times with PBS and then
fixed for 15 min with 4% paraformaldehyde in PBS, followed by
three washes with PBS. The cells were permeabilized for 5 min at
room temperature with 0.5% Triton X-100 in PBS, washed twice
with PBS, and blocked with 0.5% BSA in PBS for 20 min. Blocked
sections were then incubated at 4uC overnight with mouse anti-
cytokeratin monoclonal antibody (1:200) or anti- vimentin
monoclonal antibody(1:200) or anti- E-cadherin antibody (1:200)
or anti-a-SMA antibody (1:250).After washing in PBS, the sections
were treated with goat anti-mouse or goat anti-rabbit HRP-
conjugated secondary antibody at 37uC for 20 min. Slides were
then processed with the universal labelled streptavidin-biotin
reagents (peroxidase) and colour was developed with DAB. After
the sections were washed twice for 5 minutes with PBS, they were
counterstained with haematoxylin, dehydrated with ethanol,
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PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28915Figure 1. Phase-contrast microscopic observation and identification of primary culture cyst-lining epithelial cells. (A) Confluent
monolayer of cyst-lining epithelial cells (Magnification 6200). (B–C). Transmission electron micrographs of cyst-lining epithelial cells (Magnification
69600). B and C respectively showing the presence of adhesion plaque at tight junctions of cell-cell contact and microvilli-like coating. (D–G).
Immunocytochemistry of E-cadherin (D) (Magnification6400), cytokeratin (E) (Magnification6200), vimentin (F) (Magnification6200) and a-SMA (G)
(Magnification 6200) in cyst-derived cells.
doi:10.1371/journal.pone.0028915.g001
Figure 2. Expression of TGF-b1 in human normal kidney
tissues, ADPKD kidney tissues, RTC and CEC. (A) QRT-PCR
analysis of TGF-b1 mRNA expression. (B) Immunoblotting analysis of
TGF-b1 protein expression. Top panels were representative Western
blot images. Bottom panels were the summary data from three
independent experiments. *P,0.05 vs. control.
doi:10.1371/journal.pone.0028915.g002
Figure 3. TGF-b1 induced collagen type I expression in a
concentration- and time-dependent manner in ADPKD cyst-
lining epithelial cells. (A) TGF-b1 treatment (1–10 ng/mL, 24 h). (B)
TGF-b1 treatment (5 ng/mL, 6–36 h). Top panels were representative
Western blot images. Bottom panels were the summary data from three
independent experiments. *P,0.05 vs. control.
doi:10.1371/journal.pone.0028915.g003
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and photography. Incubation with an irrelevant non-immune
mouse IgG primary antibody served as the negative control.
Protein extraction and Western blot analysis
Tissue proteins or cell proteins were extracted by RIPA lysis
buffer (20 mM Tris, 0.1% SDS, 1% Triton X-100, 1% sodium
deoxycholate, pH 7.4) with protease inhibitor cocktail (Novagen,
USA) and phosphatase inhibitors (1 mM sodium orthovanadate,
10 mM sodium fluoride).
Fifty micrograms of total protein lysate were separated by SDS-
PAGE. After electrophoresis, proteins were transferred to poly-
vinylidene fluoride membranes. The blots were blocked with TBST
(10 mM Tris, pH 7.5, 100 mM NaCl, 0.1% Tween-20) containing
5% non-fat dry milk for 2 hours at room temperature, and then
incubated with the desired primary antibodies at 4uC overnight.
These antibodies include anti- TGF-b1(1:1000), anti- collagen I
(1:5000), anti-fibronectin (1:1000), anti-smad2 (1:1000), anti-phos-
pho-smad2 (1:500), anti-ERK1/2 (1:1000),anti-phospho-ERK1/2
(1:1000), anti-phospho-JNK1/2(1:1000), anti-JNK1(1:1000), anti-
phospho-p38 (1:1000), anti-p38 (1:1000) antibody. The membrane
was subjected to three 5-min TBST washes, and incubated at room
temperature with goat anti-mouse IgG-HRP(1:2000) or goat anti-
rabbit IgG-HRP (1:2000) (Dako, Carpiteria, CA, USA). After
subsequent washing with TBST, signals were detected with the
enhanced chemiluminescence blotting detection system (Amersham,
Arlington Heights, IL, USA). GAPDH (1:5000) were used as an
internal control. For quantification, blots of at least three
independent experiments were used.
Quantitative Real-Time Reverse-Transcriptase Polymerase
Chain Reaction
To determine the effect of rosiglitazone on collagen and
fibronectin gene expression, ADPKD cyst-lining epithelial cells
were grown in DMEM supplemented with 10% FBS until
subconfluent. Cells were arrested by 0.5% FBS for 24 hours and
Figure 4. Rosiglitazone inhibited TGF-b1-induced collagen type I and fibronectin protein and mRNA synthesis in ADPKD cyst-lining
epithelial cells in a concentration-dependent fashion. Cells were pretreated with rosiglitazone for 1 h, and then incubated with TGF-b1 for
24 h. A. collagen type I and fibronectin protein in TGF-b1-stimulated ADPKD cyst-lining epithelial cells treated with rosiglitazone. B. collagen type I
and fibronectin mRNA in TGF-b1-stimulated ADPKD cyst-lining epithelial cells treated with rosiglitazone. All results were representative of three
independent experiments with similar results. *P,0.05 vs. control; #P,0.05 vs. TGF-b1.
doi:10.1371/journal.pone.0028915.g004
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various concentrations of rosiglitazone. After 24 hours, cells were
harvested for isolation of total RNA, as described previously. RNA
gel electrophoresis was performed to confirm the quality of the
isolated RNA. The qualified RNA was subjected to reverse
transcription using PrimesScript RT reagent kit (Takara, Shiga,
Japan). The polymerase chain reaction (PCR) was performed in a
20 mL reaction containing PCR mix Sybergreen (Takara, Shiga,
Japan), each primer, and cDNA. PCR conditions were 95uC for
10 sec as initiative denaturation, followed by 40 cycles of 95uC for
5 sec, and 60uC for 20 sec. GAPDH was used as the internal
control. The primer sequences were AAC CCA CAA CGA AAT
CTA TGA C and GAG GTA TCG CCA GGA ATT GT for
TGF-b1, TGAGAGAGGGGTTGTTGGAC and AGGTTCA-
CCCTTCACACCTG for Collagen I, TGGACCAAGTTGAT-
GACACC and CACCAGGTTGCAAGTCACTG for Fibronec-
tin, and GGAAACTGTGGCGTGATG and TGGGTGTCGC-
TGTTGAAG for GAPDH. A critical threshold cycle (Ct) value,
reflecting the cycle number at which the DNA amplification was
first detected, was determined for each reaction. Relative
transcript levels were calculated as E=2
2DCt, where E is the
gene expression value and DCt is the difference in crossing points
between GAPDH and each gene.
RNA interference
Transfection of ADPKD cyst-lining epithelial cells with small
interfering RNA (siRNA) was optimized using the GAPDH
Silencer II kit (Ambion, Huntingdon, UK) according to the
manufacturer’s instructions. In brief, 8610
4 cells per 12-well plate
were transfected in suspension with 30 nmol/L siRNA and 5 mlo f
siPORT amine (Ambion) in a final volume of 1000 ml. After
48 hours, cells were lysed and RNA was extracted with TRIzol
reagent, before detection of gene expression using quantitative
polymerase chain reaction (PCR) as described below. This
protocol was found to give optimal knockdown (reliably 70% or
more reduction in GAPDH mRNA). After optimization, the same
protocol was followed for Smad2 siRNA transfection (siRNA ID
45232; Ambion) and PPARc siRNA transfection (siRNA ID 5821;
Ambion). Scrambled siRNA-transfected controls were included in
all experiments.
Statistical analysis
The data were presented as means 6 SD. Comparisons between
results from different groups were performed using Student’s t-test
or one-way analysis of variance (ANOVA), as appropriate.
Statistical significance was defined as P,0.05 in all cases.
Results
1. Identification of primary culture cyst-lining epithelial
cells and renal tubular epithelial cells
Confluent monolayer of cyst-derived cells were seen after 4–5
days culture (Fig 1A). Adhesion plaques at tight junctions of cell-
cell contact and microvilli-like coatings were found by transmission
electron micrographs (Fig1B, 1C). Then the cyst-derived cells
epithelia were detected by immunocytochemistry with cytokeratin
antibody, vimentin antibody, E-cadherin antibody and a-SMA
antibody. Positive E-cadherin and cytokeratin staining (Fig1D and
1E) and negative a- SMA staining (Fig1G) also confirmed
epithelial origin of these cells, which was consistent with the
previous studies.[31,32] The cells also expressed vimentin (Fig 1F),
which was a dedifferentiation marker. ADPKD was a neoplasm-
like disease characterized by epithelial polarity change and
dedifferentiation. In our study, primary ADPKD epithelial cells
expression vimentin was consistent with loss of differentiation.
Similar results were detected in primary culture tubular epithelial
cells (data not shown).
2. TGF-b1 expression in human ADPKD kidney tissues
and cyst-lining epithelial cells
TGF-b1 expression was studied at both mRNA (Fig 2A) and
protein level (Fig 2B) in ADPKD kidney tissues and primary cyst-
lining epithelial cells. Much higher TGF-b1 expression levels were
observed in human ADPKD kidney tissues and cyst-lining
epithelial cells compared to normal kidney tissues and primary
renal tubular epithelial cells.
3. Rosiglitazone inhibited TGF-b1-induced collagen type I
and fibronectin expression
Since collagen type I and fibronectin were the major ECM
components of ADPKD kidney tissues [33], we investigated
whether rosiglitazone could prevent TGFb1-induced ECM
components in ADPKD cyst-lining epithelial cells. As shown in
Fig 3, TGF-b1 increased collagen type I expression in a
concentration- and time-dependent manner in ADPKD cyst-
lining epithelial cells. The maximal level of collagen type I
expression appeared when ADPKD cyst-lining epithelial cells were
treated with 5 ng/mL TGF-b1 for 24 hours. Therefore, in all
subsequent experiments, the concentration of TGF-b1 was kept at
5 ng/mL and the treatment time at 24 h.
To examine the rosiglitazone dose effect on TGF-b1-induced
collagen type I and fibronectin expression, cells were pretreated
for 1 hour with 1–10 mM rosiglitazone before addition of 5 ng/ml
TGF-b1 for further 24 hours. These studies revealed that
rosiglitazone could suppress TGF-b1-induction of collagen type I
and fibronectin expression in a concentration-dependent fashion
(Fig 4).
4. TGF-b1 activated Smad2 and MAPK pathways in
ADPKD cyst-lining epithelial cells
Since activation of Smad2 was the major downstream event of
TGF-b1 signaling, we first investigated the phosphorylation of
Smad2 in human ADPKD cyst-lining epithelial cells. As shown in
Fig 5A, TGF-b1 (5 ng/mL) induced a rapid phosphorylation of
Smad2 that began within 15 minutes, peaked at 60 minutes and
then returned to baseline values by 8 hours. Results were
expressed as the ratio between phosphorylated and nonpho-
sphorylated Smad2.
Previous studies had demonstrated that MAPK pathways were
present in ADPKD cyst-lining epithelial cells [34]. Our current
study evaluated whether TGF-b1 could activate MAPK pathways
in ADPKD cyst-lining epithelial cells. As shown in Fig 5B and 5C,
Figure 5. Time course of Smad2 (A), ERK1/2 (B), p38MAPK (C) and JNK (D) activation by TGF-b1 in ADPKD cyst-lining epithelial cells.
Cells were treated with TGF-b1 (5 ng/ml) for the indicated time periods. Kinase activation was determined by western blot analysis using
phosphospecific antibodies. As controls, the protein levels of Smad2, ERK1/2, p38MAPK and JNK were determined using corresponding non-
phosphorylated form antibodies. Results of densitometric analysis, expressed as a ratio between phospho- and non-phospho-antibody, from three
independent experiments were shown. *P,0.05 vs. control.
doi:10.1371/journal.pone.0028915.g005
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within 15 minutes after TGF-b1 was added, peaked at 60 minutes.
In contrast, the JNK pathway displayed no activation in response
to TGF-b1 (Fig 5D).
5. Rosiglitazone inhibited activation of Smad2, but not
MAPK pathways in TGF-b1 –stimulated ADPKD cyst-
lining epithelial cells
To analyze the mechanisms of rosiglitazone on TGF-b1–
mediated collagen type I and fibronectin expression, the effects of
rosiglitazone on signaling transduction pathways downstream to
TGF-b1 were examined. As shown, TGF-b1 induced the
activation of P-Smad2 and rosiglitazone abrogated this response
in a dose-dependent manner at a concentration that inhibited
collagen gene expression (5 to 10 mmol/L) (Fig 6A). In contrast,
the same concentration of rosiglitazone had no effect on TGF-b1–
induced activation of ERK1/2 and p38MAPK pathways (Fig 6B,
Fig 6C). We next examined the effects of blockade of the Smad2
pathway by transfecting the Smad2 siRNA on ECM systhesis
induction by TGF-b1. Smad2 siRNA transfection (Smad2 mRNA
was decreased to 37.8% by Smad2 siRNA) significantly reduced
synthesis of collagen type I and fibronectin in TGF-b1- stimulated
cells (Fig 7).
6. Rosiglitazone had no effect on the activated Smad2
and MAPK pathways in TGF-b1 –stimulated primary renal
tubular epithelial cells
We also investigated whether rosiglitazone could prevent
TGFb1-induced ECM components in primary renal tubular
epithelial cells. As shown in Fig 8A, TGF-b1 increased collagen
type I and fibronectin expression in primary renal tubular
epithelial cells and rosiglitazone could suppress TGF-b1-induced
of ECM expression. Although TGF-b1 could activate Smad2,
ERK1/2 and p38MAPK pathways, rosiglitazone had no effect on
TGF-b1–induced activation of these three pathways (Fig 8).
7. Interaction of the Smad pathway and the MAPK
pathways in ADPKD cyst-lining epithelial cells
Previous reports had demonstrated a crosstalk between Smad
and MAPK signalling pathways [35,36]. We performed experi-
ments to evaluate the potential interaction among the pathways.
ADPKD cyst-lining epithelial cells pretreated with PD98059 or
SB203580 did not influence the activation of Smad2 on TGF-b1
treatment (Fig 9A). At the same time, the activation of ERK 1/2
and P38 in response to TGF-b1 were not blocked by inhibiting
Smad2 using siRNA (Fig 9B, Fig 9C).
8. The effects of rosiglitazone were peroxisome
proliferator-activated receptorc-dependent
To determine whether or not the action of rosiglitazone on
human ADPKD cyst-lining epithelial cells was mediated by
PPARc, we used both pharmacological and genetic approaches.
The effects of the PPARc-specific antagonist GW9662 on collagen
type I gene expression were assessed by qRT-PCR (Fig 10A). As
mentioned previously, TGF-b1 significantly enhanced collagen
gene expression, while rosiglitazone pretreatment abolished these
effects of TGF-b1. Compared with the control, GW9662 did not
affect the basal level of collagen type I gene expression. However,
GW9662 almost completely reversed the inhibitory effects of
rosiglitazone on TGF-b1-induced collagen type I expression.
We then introduced a PPARc siRNA into ADPKD cyst-lining
epithelial cells by transfection. This resulted in an 64% reduction
Figure 7. Effect of Smad2 siRNA on TGF-b1 induced collagen
type I and fibronectin mRNA expression. Smad2 was inhibited
using the Smad2 siRNA method. Cells were transfected with Smad2
siRNA for 48 h, followed by treatment with TGF-b1 for 24 h. (A) Smad2
siRNA significantly reduced collagen type I synthesis in TGF-b1-
stimulated cells. (B) Smad2 siRNA significantly reduced fibronectin
synthesis in TGF-b1-stimulated cells. (C) Smad2 mRNA was decreased to
37.8% using real-time RT–PCR in Smad2 siRNA-transfected ADPKD cyst-
lining epithelial cells. The results were representative of three
independent experiments. *P,0.05 vs. control, # P,0.05 vs. TGF-b1
alone.
doi:10.1371/journal.pone.0028915.g007
Figure 6. Evaluation of inhibitory effect of rosiglitazone on TGF-b1 induced Smad2 (A), ERK1/2 (B) and p38MAPK(C) activation in
ADPKD cyst-lining epithelial cells. Cells were pretreated with rosiglitazone for 1 h, and then incubated with rosiglitazone in the presence or
absence of TGF-b1 (5 ng/mL) for another 1h. * P,0.05 vs. TGF-b1 alone.
doi:10.1371/journal.pone.0028915.g006
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transfected with scrambled siRNA, rosiglitazone did not cause an
obvious inhibition of collagen type I gene expression induced by
TGF-b1 in PPARc knock-down cells (Fig 10B).These data
indicated that the effects of rosiglitazone on collagen type I gene
expression in human ADPKD cyst-lining epithelial cells were
PPARc-dependent.
Discussion
At present, there is no effective medical remedy and
intervention for ADPKD patients. In the past decade, therapeutic
strategies focused on the specific pathways in the cysts initiation
stage such as aberrant cAMP and mTOR activation of cystic
epithelia had been well developed [37,38], However, until now
Figure 8. The role of rosiglitazone on TGF-b1-induced primary renal tubular epithelial cells. Collagen type I and fibronectin expression in
TGF-b1-stimulated primary renal tubular epithelial cells treated with rosiglitazone (A). Cells were pretreated with rosiglitazone (10 mmol/L) for 1 h,
and then incubated with TGF-b1 for 24 h. Evaluation of inhibitory effect of rosiglitazone on TGF-b1-induced Smad2 (B), ERK1/2 (C) and p38MAPK (D)
activation in primary renal tubular epithelial cells. Cells were pretreated with rosiglitazone for 1 h, and then incubated with rosiglitazone in the
presence or absence of TGF-b1 (5 ng/mL) for another 1 h. *P,0.05 vs. control.
doi:10.1371/journal.pone.0028915.g008
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clinical trials[39,40]. On the other side, the common pathways for
chronic kidney disease progression bred some other candidate
therapeutic targets for ADPKD. Since progressive renal dysfunc-
tion in ADPKD is associated with the development of interstitial
abnormalities, particularly inflammation and fibrosis, blocking the
fibrosis process will undoubtedly provide new therapeutic avenues
for the management of this disease.
TGF-b1-induced up-regulation ECM production is well
established in glomerular mesangial cells, interstitial fibroblasts
and tubular epithelial cells in vitro. In this study, we demonstrated
ADPKD cyst-lining epithelia was another source of TGF-b1
production and might act as an important TGF-b1 responsive cell
type in kidney, which could enhance the production of collagen
type I and fibronectin and accelerate chronic kidney disease
progression under a TGF-b1 excess circumstance. Similar to
several types of cultured kidney cells, PPARc agonist rosiglitazone
reduced the expression of fibrosis-related markers induced by
TGF-b1. In contrast to the significant down-regulation of TGF-b1
in rosiglitazone treated PKD rat, TGF-b1 expression were not
altered in rosiglitazone treated ADPKD cyst-lining epithelia in
vitro(data not shown), which suggested rosiglitazone-mediated
down-regulation of TGF-b1 in vivo were not through cyst-lining
epithelia. The additive suppression of TGF-b1 induced ECM
synthesis in vitro provided more powerful evidence for rosiglita-
zone modulating TGF-b1 induced fibrogenesis and made it to be a
promising anti-fibrosis therapeutic agent for ADPKD.
TGF-b1 exerts its multiple biologic actions by activating several
intracellular signal transduction systems. The Smad family of
proteins has been recently identified as a predominant signal
transducer of TGF-b1 [10]. Heeg et al [41] indicated that Smad2
was involved in TGF-b1-induced fibronectin synthesis in renal
fibroblasts. Smad2 has also been demonstrated to mediate renal
interstitial fibrosis development in mice with experimental
aristolochic acid nephropathy [42]. Sabrine and colleagues
analysed expression of the TGF-b–Smad signalling pathway in
different Pkd1 mutant mouse models in various stages of polycystic
disease [5]. They found that increased nuclear localization of P-
Smad2 in cyst lining epithelial cells was not observed in the
initiation phase but was found at more advanced stages of PKD
which were characterized by progressive renal fibrosis. Here we
confirmed Smad2 was activated (phosphorylated) by TGF-b1i na
time-dependent manner and the up-regulation of P-Smad2 was
reduced in rosiglitazone-treated ADPKD cyst lining epithelial
cells. In addition, the blockade of Smad2 by Smad2 siRNA
attenuated the increase in collagen type I and fibronectin mRNA
expression induced by TGF-b1. These data revealed that
rosiglitazone abrogated TGF-b1 induced ECM synthesis through
Smad2 pathway.
Besides Smad proteins, MAPKs are another molecular pathway
involved in TGF-b1 signaling. A series of studies have shown that
both ERK and p38 kinase signaling pathways contribute to TGF-
b1-stimulated fibronectin and collagen production by glomerular
mesangial cells and renal fibroblasts [15,43,44]. Activation of JNK
is required for TGF-b1 induced fibronectin in human fibrosarco-
mas [14]. Previous studies have confirmed that the elevation of
ERK1/2 activity in PKD played a pivotal role in cysts
Figure 9. Crosstalk between Smad2 and MAPK signals in TGF-
b1-stimulated ADPKD cyst-lining epithelial cells. (A) Smad2
activation was not affected by inhibition of ERK or P38 MAPK pathways.
ADPKD cyst-lining epithelial cells pre-treated with PD98059 (25 mM) or
SB203580 (10 mM) for 1 h were stimulated with TGF-b1 for another 1 h.
(B) ERK activation was not affected by inhibition of the Smad2 signal.
Smad2 was inhibited using Smad2 siRNA method. (C) P38 activation
was not affected by inhibition of the Smad2 signal. The results were
representative of three independent experiments.
doi:10.1371/journal.pone.0028915.g009
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PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e28915Figure 10. Rosiglitazone inhibited TGF-b1-induced collagen type I expression in ADPKD cyst-lining epithelial cells through PPARc.
(A) Cells were incubated with GW9662 (1 mmol/L) and cultured for 48 h. Then cells were pretreated with 10 mmol/L rosiglitazone for 1 h and
incubated with TGF-b1 (5 ng/mL) for 24 h. (B) Cells were transfected with a PPARc siRNA for 48 h, then pretreated with 10 mmol/L rosiglitazone for
1 h and incubated with TGF-b1(5 ng/mL) for 24 h. (C) PPARc mRNA was decreased to 36% using real-time RT–PCR in PPARc siRNA-transfected
ADPKD cyst-lining epithelial cells. The results were representative of three independent experiments. *P,0.05 vs. control; #P,0.05 vs. TGF-b1 alone
D P,0.05 vs. rosiglitazone + TGF-b1.
doi:10.1371/journal.pone.0028915.g010
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cyst growth in the pcy mouse model of PKD [47]. PPARc ligand
inhibited the progression of polycystic kidney disease in a model of
human ARPKD by inhibiting ERK signaling pathway mediated
cell proliferation [27]. However, in this study, we proved that
TGF-b1 could induce the phosphorylation of ERK and p38
MAPK but had no effect on activation of JNK. The activation of
ERK and P38 induced by TGF-b1 were unaltered in rosiglita-
zone-treated ADPKD cyst lining epithelial cells. These data
implied that the inhibitory effect of rosiglitazone on TGF-b1-
stimulated ECM expression mainly operated through modulations
of the SMAD pathway rather than the MAPK pathways in
ADPKD cyst lining epithelial cells.
In primary renal tubular epithelia cells, TGF-b1 also increased
collagen type I and fibronectin expression which could be
inhibited by rosiglitazone. But the activation of Smad2, ERK1/
2 and p38MAPK pathways induced by TGF-b1 were not blocked
by rosiglitazone, which suggested other pathways except Smad2
and MAPK pathways might be involved in the anti-fibrosis effect
of rosiglitazone. Guo et al had reported that another PPAR-
gamma agonist pioglitazone could suppress TGF-b1-induced
fibronectin expression in mesangial cells through inhibiting
PPAR-c-dependent AP-1 activation instead of modulating Smad
and MAPK pathways [48]. Therefore, the molecular mechanisms
of primary renal tubular epithelia responding to rosiglitazone need
to be elucidated in further studies.
There is now ample evidence showing a crosstalk between
MAPK and Smad signalling pathways. In human mesangial cells,
ERK activity enhances TGFb1-induced collagen expression by
augmenting Smad signaling [49]. Given the involvement of the
SMAD pathway and the MAPK pathways in TGF-b1 signaling of
ADPKD cyst-lining epithelial cells, it is intriguing to speculate that
potential cross-talk exists between these two types of signaling
pathways. However, in our current study, PD98059 and
SB203580 failed to prevent TGF-b1–induced Smad2 activation,
and Smad2 siRNA failed to prevent TGF-b1–induced ERK and
P38 MAPK activation which demonstrated that there were no
crosstalk between Smad2 and MAPK signals in ADPKD cyst-
lining epithelial cells. Lack of crosstalk indicated the possibility of
combination therapy with PPARc agonists and MAPK pathway
blocking agents such as ERK inhibitor to enhance therapeutic
efficacy for ADPKD.
PPARc agonists may exert multiple biological effect through
PPARc dependent and independent manner. In this
study,GW9662 completely reversed the inhibitory effects of
rosiglitazone on TGF-b1-induced collagen type I gene expression
in ADPKD cyst-lining epithelial cells. In addition, knocking-down
PPARc expression by siRNA blocked the inhibitory effects of
rosiglitazone on TGF-b1-stimulated collagen gene expression.
These results indicated that the effects of rosiglitazone were due to
PPARc activation. A recent study in renal mesangial cells and
fibroblasts demonstrated that a natural PPARc ligand 15d-PGJ2
induced hepatocyte growth factor (HGF) expression through a
PPARc-dependent pathway, and the activation of HGF played a
central role in 15d-PGJ2’s inhibition of TGF-b1-induced fibro-
genesis [50]. Identifying the role of HGF in TGF-b1-treated
ADPKD cyst-lining epithelial cells and their possible modulation
by rosiglitazone deserves further study.
In summary, the present study demonstrated that ADPKD cyst-
lining epithelial cells were involved TGF-b1 mediated fibrogenesis
and rosiglitazone could inhibit TGFb1-induced collagen type I
and fibronectin expression in ADPKD cyst-lining epithelial cells
through modulating the Smad pathway but not MAPK pathways.
Moreover, the results showed that these effects of rosiglitazone
were mediated by PPARc activation. These findings may provide
therapeutic basis of the promising candidate drug in polycystic
kidney disease.
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